Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT00470977
Show Display Options
Rank Status Study
1 Completed Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
Conditions: Coats' Disease;   Idiopathic Retinal Telangiectasia;   Retinal Angiomatous Proliferation;   Polypoidal Choroidal Vasculopathy;   Pseudoxanthoma Elasticum;   Pathological Myopia;   Multi-focal Choroiditis;   Rubeosis Iridis;   Von Hippel Lindau Disease;   BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)
Intervention: Drug: ranibizumab injection (0.5 mg)

Indicates status has not been verified in more than two years